Author: Wallin, Johan; Svenningsson, Per
Title: Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease Cord-id: iscloqqk Document date: 2021_5_25
ID: iscloqqk
Snippet: Parkinson’s disease (PD) is a neurodegenerative disorder where misfolded alpha-synuclein-enriched aggregates called Lewy bodies are central in pathogenesis. No neuroprotective or disease-modifying treatments are currently available. Parkinson’s disease is considered a multifactorial disease and evidence from multiple patient studies and animal models has shown a significant immune component during the course of the disease, highlighting immunomodulation as a potential treatment strategy. The
Document: Parkinson’s disease (PD) is a neurodegenerative disorder where misfolded alpha-synuclein-enriched aggregates called Lewy bodies are central in pathogenesis. No neuroprotective or disease-modifying treatments are currently available. Parkinson’s disease is considered a multifactorial disease and evidence from multiple patient studies and animal models has shown a significant immune component during the course of the disease, highlighting immunomodulation as a potential treatment strategy. The immune changes occur centrally, involving microglia and astrocytes but also peripherally with changes to the innate and adaptive immune system. Here, we review current understanding of different components of the PD immune response with a particular emphasis on the leukotriene pathway. We will also describe evidence of montelukast, a leukotriene receptor antagonist, as a possible anti-inflammatory treatment for PD.
Search related documents:
Co phrase search for related documents- adaptive immune response and lung tissue damage: 1, 2, 3
- adaptive immunity and adjuvant therapy: 1
- adaptive immunity and locally act: 1
- adaptive immunity and lung tissue: 1, 2, 3, 4, 5, 6, 7
- adaptive immunity and lung tissue damage: 1, 2
- adaptive immunity and macrophage neutrophil: 1
- adaptive innate and adjuvant therapy: 1, 2
- adaptive innate and locally act: 1
- adaptive innate and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- adaptive innate and lung tissue damage: 1, 2, 3
- adaptive innate and macrophage neutrophil: 1, 2, 3
- lung tissue and lymph system: 1, 2
- lung tissue and macrophage neutrophil: 1, 2, 3, 4, 5, 6, 7
- lung tissue damage and macrophage neutrophil: 1, 2
Co phrase search for related documents, hyperlinks ordered by date